What are the most valued startups in the healthcare AI market?

Last updated: 13 March 2026

Download our beautiful pitch about the healthcare AI market

market research pitch 2026 statistics healthcare AI market

In our healthcare AI market deck, you will find everything you need to understand the market

This is a continuously updated ranking of the top 100 startups in the healthcare AI market, sorted by current or estimated valuation.

We built this list by combining publicly available data, funding disclosures, market cap figures, and structured valuation estimates for private companies.

We update this list every month so you always have access to the latest data on healthcare AI startup valuations.

And if you want to better understand this new industry, you can download our pitch covering the healthcare AI market.

A quick summary table

Most valuable healthcare AI startup Tempus ($14.0B)
Second most valuable healthcare AI startup OpenEvidence ($12.0B)
Median healthcare AI startup valuation ~$460M
Share of total valuation captured by the top 10 ~56%
Top healthcare AI valuation vs. median ~30x
Median valuation-to-capital-raised ratio ~3.0x
Healthcare AI startups valued at $1B+ 30
market map chart top companies startups healthcare AI market

In our healthcare AI market deck, we will give you useful market maps and grids

Top startups in the healthcare AI market ranked by valuation

Here is an updated table that ranks the top startups in the healthcare AI market based on their latest reported or estimated valuations.

If you want more details about their fundraising activity, you can check our list of the startups who have raised the most funding in the healthcare AI market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Tempus AI precision medicine platform $14.0B Full Confidence Public Market Cap Observed $1.4B Full Confidence
2 OpenEvidence Medical search for doctors $12.0B Full Confidence Announced Private Round Valuation Observed $735M Full Confidence
3 Commure Healthcare operations AI platform $5.0B–$6.5B Partial Confidence Proxy-Based Estimate Estimated $500M Partial Confidence
4 Isomorphic Labs AI drug design company $5.0B–$6.0B Partial Confidence Implied Valuation from Raise Implied $600M Partial Confidence
5 XtalPi AI drug and materials R&D $5.4B Full Confidence Public Market Cap Observed $1.6B Full Confidence
6 Abridge AI clinical documentation platform $5.1B–$5.5B Strong Confidence Announced Private Round Valuation Implied $758M Strong Confidence
7 Insilico Medicine AI drug discovery platform $4.0B Full Confidence Public Market Cap Observed $806M Full Confidence
8 Hippocratic AI Generative AI healthcare agents $3.5B Full Confidence Announced Private Round Valuation Observed $370M Full Confidence
9 Formation Bio AI-native drug development pharma $2.8B–$4.0B Partial Confidence Implied Valuation from Raise Implied $528M Partial Confidence
10 Xaira Therapeutics AI-native drug discovery biotech $2.7B–$4.0B Partial Confidence Implied Valuation from Raise Implied $1.0B Partial Confidence
11 Innovaccer Healthcare data and AI cloud $3.0B–$3.5B Strong Confidence Announced Private Round Valuation Implied $643M Strong Confidence
12 Komodo Health Healthcare data intelligence platform $3.0B–$3.4B Strong Confidence Comparables-Based Estimate Estimated $514M Strong Confidence
13 Freenome AI blood cancer screening $1.8B–$2.6B Partial Confidence Implied Valuation from Raise Implied $1.4B Partial Confidence
14 HeartFlow AI coronary imaging diagnostics $2.1B Full Confidence Public Market Cap Observed $935M Full Confidence
15 Recursion Pharmaceuticals AI drug discovery platform $2.1B Full Confidence Public Market Cap Observed $1.4B Full Confidence
16 Pathos AI AI oncology drug development $1.6B–$1.9B Strong Confidence Announced Private Round Valuation Observed $457M Strong Confidence
17 insitro AI-driven drug discovery $1.4B–$2.1B Partial Confidence Comparables-Based Estimate Estimated $643M Partial Confidence
18 Generate:Biomedicines Generative AI protein therapeutics $1.6B Full Confidence Public Market Cap Observed $1.1B Full Confidence
19 AbCellera Antibody discovery technology platform $1.5B Full Confidence Public Market Cap Observed $638M Full Confidence
20 Ambience Healthcare Ambient clinical documentation AI $1.25B–$1.35B Strong Confidence Announced Private Round Valuation Implied $313M Strong Confidence
21 Chai Discovery Frontier AI molecular design $1.3B Full Confidence Announced Private Round Valuation Observed $230M Full Confidence
22 SmarterDx Revenue integrity clinical AI $1.2B–$1.3B Partial Confidence Proxy-Based Estimate Estimated $71M Partial Confidence
23 Viz.ai AI care coordination platform $1.1B–$1.4B Partial Confidence Revenue or ARR Multiple Estimate Estimated $250M Partial Confidence
24 AKASA AI revenue cycle automation $1.0B–$1.4B Partial Confidence Implied Valuation from Raise Implied $205M Partial Confidence
25 Owkin AI biotech for drug discovery $1.0B–$1.3B Partial Confidence Comparables-Based Estimate Estimated $304M Partial Confidence
26 Aidoc Clinical AI for hospitals $900M–$1.3B Strong Confidence Implied Valuation from Raise Implied $380M Strong Confidence
27 Medable Decentralized clinical trial software $900M–$1.3B Partial Confidence Comparables-Based Estimate Estimated $507M Partial Confidence
28 Clarify Health Solutions Healthcare analytics and payments $900M–$1.2B Partial Confidence Comparables-Based Estimate Estimated $328M Partial Confidence
29 Immunai Immune mapping for therapeutics $900M–$1.2B Partial Confidence Comparables-Based Estimate Estimated $295M Partial Confidence
30 Cleerly AI heart disease imaging $850M–$1.2B Partial Confidence Implied Valuation from Raise Implied $383M Partial Confidence
31 Cohere Health Prior authorization automation software $800M–$1.1B Strong Confidence Implied Valuation from Raise Implied $196M Strong Confidence
32 Valo Health AI-powered drug development $800M–$1.1B Partial Confidence Comparables-Based Estimate Estimated $400M Partial Confidence
33 Iambic Therapeutics AI-designed therapeutics $800M–$1.1B Partial Confidence Implied Valuation from Raise Implied $303M Partial Confidence
34 Genesis Therapeutics Molecular AI drug discovery $800M–$1.0B Partial Confidence Revenue or ARR Multiple Estimate Estimated $256M Partial Confidence
35 Relay Therapeutics Precision oncology drug discovery $900M Full Confidence Public Market Cap Observed $980M Full Confidence
36 Huma Digital health AI platform $700M–$1.0B Partial Confidence Revenue or ARR Multiple Estimate Estimated $235M Partial Confidence
37 Exo Handheld ultrasound with AI $600M–$900M Low Confidence Comparables-Based Estimate Estimated $364M Low Confidence
38 Lunit Cancer diagnostics AI $724M Full Confidence Public Market Cap Observed $313M Full Confidence
39 PathAI AI-powered pathology platform $600M–$800M Partial Confidence Comparables-Based Estimate Estimated $251M Partial Confidence
40 Exscientia AI-driven drug discovery $688M Full Confidence Acquisition Value Observed $894M Full Confidence
41 Suki AI clinical documentation assistant $550M–$700M Strong Confidence Announced Private Round Valuation Estimated $165M Strong Confidence
42 CytoReason AI disease models for pharma $500M–$700M Partial Confidence Implied Valuation from Raise Implied $100M Partial Confidence
43 Qure.ai Medical imaging analysis AI $500M–$650M Strong Confidence Implied Valuation from Raise Estimated $121M Strong Confidence
44 Profluent Frontier AI protein design $500M–$650M Strong Confidence Implied Valuation from Raise Implied $150M Strong Confidence
45 Rad AI Radiology reporting workflow AI $525M–$600M Strong Confidence Announced Private Round Valuation Observed $147M Strong Confidence
46 Nabla Ambient AI clinical assistant $450M–$650M Strong Confidence Implied Valuation from Raise Implied $114M Strong Confidence
47 Saama AI clinical trial analytics $450M–$650M Low Confidence Proxy-Based Estimate Estimated $75M Low Confidence
48 BenchSci Preclinical research AI platform $450M–$550M Partial Confidence Comparables-Based Estimate Estimated $157M Partial Confidence
49 Qventus AI hospital operations automation $420M–$550M Strong Confidence Announced Private Round Valuation Estimated $200M Strong Confidence
50 METiS Therapeutics AI nanodelivery drug platform $400M–$550M Strong Confidence Implied Valuation from Raise Implied $292M Strong Confidence
51 Ibex Medical Analytics AI cancer pathology diagnostics $380M–$520M Strong Confidence Comparables-Based Estimate Estimated $104M Strong Confidence
52 Notable Healthcare workflow automation platform $350M–$550M Partial Confidence Comparables-Based Estimate Estimated $116M Partial Confidence
53 RapidAI Stroke and vascular imaging AI $350M–$500M Partial Confidence Comparables-Based Estimate Estimated $100M Partial Confidence
54 Ultromics Echo AI heart failure detection $350M–$500M Partial Confidence Implied Valuation from Raise Implied $113M Partial Confidence
55 Eko Health AI digital stethoscope diagnostics $350M–$500M Partial Confidence Implied Valuation from Raise Implied $161M Partial Confidence
56 Proscia Digital pathology AI software $350M–$450M Strong Confidence Implied Valuation from Raise Implied $119M Strong Confidence
57 Lindus Health AI-enabled clinical trial CRO $340M–$460M Strong Confidence Implied Valuation from Raise Implied $78M Strong Confidence
58 Iterative Health AI for GI diagnostics $320M–$460M Partial Confidence Comparables-Based Estimate Estimated $185M Partial Confidence
59 Nym Autonomous medical coding software $320M–$450M Strong Confidence Implied Valuation from Raise Implied $95M Strong Confidence
60 CodaMetrix AI medical coding automation $330M–$420M Partial Confidence Comparables-Based Estimate Estimated $107M Partial Confidence
61 Regard AI clinical insights platform $320M–$380M Strong Confidence Implied Valuation from Raise Implied $81M Strong Confidence
62 Biofourmis AI-enabled virtual care platform $250M–$450M Low Confidence Proxy-Based Estimate Estimated $445M Low Confidence
63 SOPHiA GENETICS Clinical genomics analytics platform $341M Full Confidence Public Market Cap Observed $476M Full Confidence
64 Corti Healthcare conversation AI copilot $280M–$380M Partial Confidence Comparables-Based Estimate Estimated $92M Partial Confidence
65 Counterpart Health AI physician enablement platform $250M–$400M Low Confidence Proxy-Based Estimate Estimated N/A Low Confidence
66 Atomwise AI small-molecule drug discovery $290M–$340M Strong Confidence Announced Private Round Valuation Observed $218M Strong Confidence
67 Aqemia Physics-based AI drug discovery $250M–$350M Partial Confidence Implied Valuation from Raise Implied $101M Partial Confidence
68 Tandem Health Clinician documentation copilot $270M–$320M Strong Confidence Implied Valuation from Raise Implied $60M Strong Confidence
69 Unlearn Clinical trial digital twins $260M–$310M Partial Confidence Implied Valuation from Raise Implied $135M Partial Confidence
70 Aignostics Pathology AI for biopharma $240M–$300M Strong Confidence Implied Valuation from Raise Implied $55M Strong Confidence
71 Causaly Biomedical research AI platform $220M–$300M Partial Confidence Implied Valuation from Raise Implied $91M Partial Confidence
72 Turbine Simulated-cell drug discovery platform $170M–$310M Strong Confidence Implied Valuation from Raise Implied $55M Strong Confidence
73 QuantHealth Clinical trial simulation AI $180M–$240M Partial Confidence Comparables-Based Estimate Estimated $20M Partial Confidence
74 Verge Genomics AI neurology drug discovery $170M–$250M Partial Confidence Comparables-Based Estimate Estimated $134M Partial Confidence
75 Healx Rare-disease drug discovery AI $180M–$230M Partial Confidence Revenue or ARR Multiple Estimate Estimated $115M Partial Confidence
76 Tandem AI AI plus physics drug discovery $150M–$220M Strong Confidence Implied Valuation from Raise Implied $82M Strong Confidence
77 Iktos Generative AI drug discovery $140M–$220M Partial Confidence Comparables-Based Estimate Estimated $16M Partial Confidence
78 DeepScribe Ambient AI medical scribe $120M–$220M Partial Confidence Revenue or ARR Multiple Estimate Estimated $39M Partial Confidence
79 AliveCor Personal ECG monitoring AI $120M–$200M Partial Confidence Revenue or ARR Multiple Estimate Estimated $118M Partial Confidence
80 Frontera Health Autism care AI tools $130M–$180M Strong Confidence Implied Valuation from Raise Implied $32M Strong Confidence
81 Zebra Medical Vision AI radiology decision support $110M–$194M Strong Confidence Acquisition Value Observed $57M Strong Confidence
82 Caption Health AI-guided ultrasound software $150M Full Confidence Acquisition Value Observed $59M Full Confidence
83 Manas AI AI cancer drug discovery $120M–$180M Partial Confidence Implied Valuation from Raise Implied $51M Partial Confidence
84 ClosedLoop Predictive AI for healthcare costs $120M–$180M Low Confidence Revenue or ARR Multiple Estimate Estimated $48M Low Confidence
85 Janus AI (Janus Health) Revenue cycle automation AI $120M–$170M Partial Confidence Implied Valuation from Raise Implied $63M Partial Confidence
86 Arterys Cloud AI medical imaging $110M–$170M Low Confidence Acquisition Value Estimated $67M Low Confidence
87 Augmedix Ambient AI medical documentation $139M Full Confidence Acquisition Value Observed $195M Full Confidence
88 Sift Healthcare Healthcare payments AI analytics $100M–$140M Partial Confidence Implied Valuation from Raise Implied $40M Partial Confidence
89 Ezra AI full-body MRI screening $90M–$150M Low Confidence Acquisition Value Estimated $43M Low Confidence
90 Paige AI for digital pathology $81M Full Confidence Acquisition Value Observed $190M Full Confidence
91 BenevolentAI AI drug discovery platform $60M–$90M Low Confidence Proxy-Based Estimate Estimated $528M Low Confidence
92 SigTuple AI diagnostics from microscopy $60M–$90M Low Confidence Revenue or ARR Multiple Estimate Estimated $50M Low Confidence
93 Quris-AI AI drug safety prediction $60M–$90M Low Confidence Proxy-Based Estimate Estimated $28M Low Confidence
94 Empatica Wearable health monitoring AI $50M–$80M Partial Confidence Revenue or ARR Multiple Estimate Estimated $33M Partial Confidence
95 Lantern Pharma AI-guided oncology drug development $47M Full Confidence Public Market Cap Observed $101M Full Confidence
96 Kheiron Medical Technologies AI breast cancer screening $30M–$60M Low Confidence Acquisition Value Estimated $22M Low Confidence
97 Memora Health Care navigation patient engagement $20M–$50M Low Confidence Proxy-Based Estimate Estimated $81M Low Confidence
98 OneThree Biotech AI-driven drug discovery platform $8M–$15M Low Confidence Comparables-Based Estimate Estimated $4M Low Confidence
99 Deep 6 AI Trial matching and recruitment AI $10M Full Confidence Acquisition Value Observed $44M Full Confidence
100 Olive AI Healthcare admin automation AI $0–$10M Low Confidence Proxy-Based Estimate Estimated $902M Low Confidence
chart market size 2026 healthcare AI market

In our healthcare AI market deck, we provide the data and the context to understand it

Key valuation trends in the healthcare AI market

OpenEvidence's $12.0B valuation on $735M in total funding gives the company a 16.3x multiple, making OpenEvidence easily the most capital-efficient startup among the ten highest-valued healthcare AI companies in the dataset.

Clinical documentation AI is the dominant category in the upper tier of this ranking. Abridge, Ambience Healthcare, Rad AI, and Nabla together command roughly $7.7B in combined valuation on approximately $1.3B in total funding raised.

Hippocratic AI reached a $3.5B valuation on just $370M raised (a 9.5x multiple), which suggests that investors in the healthcare AI market price generative AI healthcare agents at a steep premium over traditional health IT software companies.

Five acquired healthcare AI companies (Exscientia, Paige, Augmedix, Caption Health, and Deep 6 AI) raised a combined $1.4B but exited for roughly $1.1B total. These acquisitions collectively destroyed approximately $300M in aggregate investor capital.

Relay Therapeutics trades at $900M on $980M raised, and SOPHiA GENETICS trades at $341M on $476M raised. Both public healthcare AI companies are currently valued below their cumulative funding.

Among the 20 highest-valued healthcare AI companies, only seven are publicly traded. The vast majority of healthcare AI value creation remains locked inside private markets and inaccessible to public investors.

Cohere Health, Qventus, and Nym collectively raised under $500M yet command roughly $1.8B in combined midpoint valuation, signaling strong investor conviction in AI-driven healthcare operations and revenue cycle automation.

Tempus, the most valuable healthcare AI company at $14.0B, has also been the most active acquirer in the space (absorbing Paige and Arterys). This pattern suggests that platform consolidation is accelerating at the top of the healthcare AI market.

Insights

  • OpenEvidence turns $735M in funding into a $12.0B valuation (16.3x), making the company the most capital-efficient healthcare AI startup among the top 10 by a wide margin.
  • Clinical documentation AI startups like Abridge, Ambience Healthcare, Rad AI, and Nabla command ~$7.7B in combined valuation on just ~$1.3B raised, far outpacing most healthcare AI drug discovery peers on a dollar-for-dollar basis.
  • Five acquired healthcare AI startups (Exscientia, Paige, Augmedix, Caption Health, Deep 6 AI) raised $1.4B combined but exited for only ~$1.1B, destroying roughly $300M in total investor capital.
  • Only 7 of the 20 most valuable healthcare AI companies are publicly traded, meaning most of the sector's value creation remains locked in private markets.
  • Tempus leads in both valuation ($14.0B) and M&A activity (acquiring Paige and Arterys), pointing to accelerating platform consolidation at the top of the healthcare AI market.
  • Cohere Health, Qventus, and Nym raised under $500M combined but sit at ~$1.8B in total valuation, reflecting strong investor demand for AI applied to healthcare operations and revenue cycle management.
chart tempus AI healthcare ai

In our healthcare AI market deck, we identify repeatable patterns you can use if you’re building in this market

A few words about our methodology

As you can see, we built a database that ranks startups in the healthcare AI market based on their current valuation.

Estimating healthcare AI startup valuations is not always straightforward. Many healthcare AI companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed healthcare AI companies, or official acquisition prices.

When a healthcare AI startup is publicly listed, we use its current market capitalization as the reference valuation.

If a healthcare AI company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, or customer traction, combined with valuation multiples from comparable companies in the healthcare AI market.

When direct financial data is not available, we may rely on carefully selected comparable healthcare AI startups and other signals such as hiring growth, investor quality, or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each healthcare AI startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the healthcare AI market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

market growth rate cagrhealthcare AI market

In our healthcare AI market deck, we answer all the common questions from investors and entrepreneurs

Related blog posts

- What is the latest news in healthcare AI?

- What is the latest funding news in healthcare AI?

- What is the latest update in healthcare AI?

- How funding activity has changed in healthcare AI

- What are the latest fundraising trends in healthcare AI?

- What is the real size of the healthcare AI market?

- A complete list of business models in the healthcare AI market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog